Figure 1 – Graphical Study Design of Example 1




Figure 2 – 3 cartridges for injections




Figure 3 – Body mass index (BMI) for age percentiles by gender: Boys, 2 to 20 years




Figure 4 – Body mass index (BMI) for age percentiles by gender: Girls, 2 to 20 years




Figure 5 – Mean ± SEM plasma glucose per treatment group in adult patients - evaluable PD population




Figure 6 – Mean ± SEM plasma glucose per treatment group in pediatric patients – evaluable PD population




Figure 7 – Median plasma glucose (mmol/L) per treatment group in adult patients - evaluable PD population




Figure 8 – Median plasma glucose (mmol/L) per treatment group in pediatric patients - evaluable PD population




Figure 9 – Median glucagon (ng/L) per treatment group in adult patients - evaluable PD population




Figure 10 – Median glucagon (ng/L) per treatment group in pediatric patients - evaluable PD population




Figure 11 – Median plasma insulin (pmol/L) per treatment group in adult patients - evaluable PD population




Figure 12 – Median plasma insulin (pmol/L) per treatment group in pediatric patients - evaluable PD population




Figure 13 – Median C-peptide (nmol/L) per treatment group in adult patients - evaluable PD population




Figure 14 – Median C-peptide (nmol/L) per treatment group in pediatric patients - evaluable PD population




Figure 15 – Mean (+ SD) lixisenatide plasma concentrations by treatment (full PK population, linear scale)




Figure 16 – Mean (+SD) lixisenatide plasma concentrations by treatment (evaluable PK population, linear scale)




Figure 17 – Graphical Study Design of Example 3

